Scholar Rock, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.scholarrock.com
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- Conditions
- Neuromuscular ManifestationsSpinal Muscular AtrophyAnti-myostatinSpinal Muscular Atrophy Type 3SMASpinal Muscular Atrophy Type 2
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT07047144
- Locations
- πΊπΈ
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
πΊπΈNeurology Rare Disease Center, Denton, Texas, United States
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
- Conditions
- SMA
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Scholar Rock, Inc.
- Registration Number
- NCT06877689
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Conditions
- Overweight and Obesity
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT06445075
- Locations
- πΊπΈ
ProSciento CRU, Chula Vista, California, United States
πΊπΈAdventHealth Translational Research Institute, Orlando, Florida, United States
πΊπΈGreat Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
- Conditions
- Spinal Muscular AtrophySpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMANeuromuscular DiseasesMuscular AtrophyAtrophyMuscular Atrophy, SpinalNeuromuscular ManifestationsAnti-myostatin
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT05626855
- Locations
- πΊπΈ
Phoenix Childrens Hospital, Phoenix, Arizona, United States
πΊπΈUCSD Altman Clinical and Translational Research, La Jolla, California, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
- Conditions
- Spinal Muscular AtrophyNeuromuscular DiseasesAtrophyMuscular Atrophy, SpinalAnti-myostatinSpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMAMuscular AtrophyNeuromuscular Manifestations
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT05156320
- Locations
- πΊπΈ
Children's of Alabama, Birmingham, Alabama, United States
πΊπΈPhoenix Children's Hospital, Phoenix, Arizona, United States
πΊπΈChildren's Hospital of Los Angeles, Los Angeles, California, United States
- Prev
- 1
- 2
- Next